

14th July 2020

- | | |
|---|---|
| <p>(1) BSE Ltd
Listing Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001</p> | <p>(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai - 400 051</p> |
|---|---|

Scrip Code: 500087

Scrip Code: CIPLA EQ

- (3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

**Sub: Press Release – Cipla receives final approval for generic version of Shire’s Firazyr®
(Icatibant Injectable Pre-Filled Syringe 30mg/3mL)**

Dear Sir / Madam,

Please find enclosed press release dated 14th July 2020 for the captioned subject.

Kindly acknowledge the receipt

This is for your information and records.

Thanking you,

**Yours faithfully,
For Cipla Limited**

**Rajendra Chopra
Company Secretary**

Encl.as above

Prepared by: Juzer Masta



Press Release

Cipla receives final approval for generic version of Shire's Firazyr[®] (Icatibant Injectable Pre-Filled Syringe 30mg/3mL)

Mumbai, India; July 14, 2020: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla") today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Icatibant Injectable 30mg/3mL from the United States Food and Drug Administration (US FDA).

Cipla's Icatibant Injectable Pre-Filled Syringe 30mg/3mL is AP-rated generic version of Shire's Firazyr[®]. Icatibant injection is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older. According to IQVIA (IMS Health), Firazyr[®] and its generic equivalents had US sales of approximately \$270M for the 12-month period ending May 2020.

About Cipla:

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT May'20), 3rd largest in the pharma private market in South Africa (IQVIA MAT May'20), and is among the most dispensed generic players in the U.S. For over eight decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of

choice to global health bodies, peers and all stakeholders. For more, please visit www.cipla.com, or click on [Twitter](#), [Facebook](#), [LinkedIn](#).

For queries, please contact:

Corporate Communications

Heena Kanal

E-Mail: CorpComm@cipla.com

Investor Relations

Naveen Bansal

E-Mail: Investor.Relations@cipla.com